Literature DB >> 21887566

A retrospective analysis of 2000 cases with colorectal carcinoma.

G Basdanis1, A Mekras, V N Papadopoulos, E Karamanlis, D Paramythiotis, D Mekras, D Panagiotou, S Panidis, A Michalopoulos.   

Abstract

PURPOSE: Colorectal cancer (CRC) is a major cause of death in the western world and a leading cause of cancer-related death. It is one of the most common human malignancies with >300,000 cases both in the United States and in the European Union each year. The present study was conducted to assess differences in various variables of CRC, such as location of the tumor, differentiation, Dukes classification, 5-year survival and possible changes in these patterns during the examined period.
METHODS: We collected data on 2000 patients with colorectal cancer, diagnosed and treated from 1960 to 2008 in 1st Propedeutic Surgical Clinic of Aristotle's University, Thessaloniki.
RESULTS: Of 2000 cases reviewed, cancer was almost equal presented to both sexes, for all groups. Rectum was the most common tumor location in all analyzed groups (40.1%). The most common tumor differentiation was the moderate one (68.5%). Concerning tumor staging, Dukes' B tumors were most common (42.5%), and the cancer-related 5-year survival was increased by the time from 42 to 71%.
CONCLUSION: In the past 20 years, considerable improvements have been made in colorectal cancer therapy, and patients had received more sophisticated and multidisciplinary treatments, resulting in a better 5-year survival rate.

Entities:  

Mesh:

Year:  2011        PMID: 21887566     DOI: 10.1007/s10151-011-0744-y

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN: 1123-6337            Impact factor:   3.781


  9 in total

1.  Prognostic significance of mucinous component in colorectal carcinoma.

Authors:  V N Papadopoulos; A Michalopoulos; S Netta; G Basdanis; D Paramythiotis; A Zatagias; P Berovalis; N Harlaftis
Journal:  Tech Coloproctol       Date:  2004-11       Impact factor: 3.781

2.  Epidemiological trends of colorectal cancer in the Nordic countries.

Authors:  N Malila; T Hakulinen
Journal:  Scand J Surg       Date:  2003       Impact factor: 2.360

3.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Valérie Boige; Anne Cayre; Delphine Le Corre; Emmanuel Buc; Marc Ychou; Olivier Bouché; Bruno Landi; Christophe Louvet; Thierry André; Fréderic Bibeau; Marie-Danièle Diebold; Philippe Rougier; Michel Ducreux; Gorana Tomasic; Jean-François Emile; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

4.  Trends in colorectal cancer incidence and mortality.

Authors:  L Gibbons; C Waters; Y Mao; L Ellison
Journal:  Health Rep       Date:  2001       Impact factor: 4.796

5.  Gender differences in colorectal cancer incidence, mortality, hospitalizations and surgical procedures in Canada.

Authors:  Ru-Nie Gao; C Ineke Neutel; Elaine Wai
Journal:  J Public Health (Oxf)       Date:  2008-04-28       Impact factor: 2.341

6.  Rise of colorectal cancer in Singapore: an epidemiological review.

Authors:  Mark T C Wong; Kong Weng Eu
Journal:  ANZ J Surg       Date:  2007-06       Impact factor: 1.872

7.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup.

Authors:  S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish
Journal:  N Engl J Med       Date:  1993-12-30       Impact factor: 91.245

8.  [Descriptive epidemiology of malignant tumors of the colon and rectum].

Authors:  F La Rosa; P Tozzi; G Saltalamacchia; R Vitali
Journal:  Ann Ig       Date:  1989 Sep-Oct

9.  Differences in colorectal cancer survival between European and US populations: the importance of sub-site and morphology.

Authors:  G Gatta; L Ciccolallo; R Capocaccia; M P Coleman; T Hakulinen; H Møller; F Berrino
Journal:  Eur J Cancer       Date:  2003-10       Impact factor: 9.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.